Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2007, the company has made significant strides in developing innovative treatments for patients suffering from musculoskeletal conditions. Flexion is particularly known for its flagship product, Zilretta, a unique extended-release formulation of triamcinolone acetonide designed to provide long-lasting pain relief for osteoarthritis of the knee. With a focus on advancing pain management solutions, Flexion Therapeutics has established a strong market position, recognised for its commitment to improving patient outcomes. The company operates primarily in the US, with aspirations to expand its reach globally. Through its dedication to research and development, Flexion continues to set itself apart in the competitive landscape of therapeutics, aiming to address unmet medical needs in the field of pain management.
DitchCarbon Score
How does Flexion Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Flexion Therapeutics, Inc.'s score of 23 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Flexion Therapeutics, Inc.'s reported carbon emissions
Flexion Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or evaluate their climate commitments. The absence of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, Flexion Therapeutics may need to establish clear targets and commitments to align with industry standards and expectations for climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Flexion Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
